P2, N=18, Recruiting, H. Lee Moffitt Cancer Center and Research Institute

P1, N=42, Recruiting, Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting

Bispecific antibodies such as blinatumomab (anti-CD19), antibody-drug conjugates like inotuzumab ozogamicin (anti-CD22), and monoclonal antibodies such as daratumumab (anti-CD38) have demonstrated efficacy in relapsed or refractory disease with improved safety profiles. The integration of targeted and immune-based therapies into conventional regimens represents a decisive step toward precision medicine, aiming to enhance survival outcomes while reducing treatment-related toxicity and improving quality of life in ALL children. This review aims to provide a comprehensive overview of the current understanding of ALL pathobiology and therapeutic approaches, with particular emphasis on the expanding role of immunotherapeutic strategies in pediatric disease.

P3, N=800, Not yet recruiting, Janssen Research & Development, LLC | Trial completion date: Jun 2030 --> Jun 2029

P2, N=29, Suspended, City of Hope Medical Center | Recruiting --> Suspended

P4, N=15, Recruiting, University Health Network, Toronto | Not yet recruiting --> Recruiting | Trial completion date: Sep 2025 --> Oct 2026 | Trial primary completion date: Apr 2025 --> Jun 2026

P1, N=135, Active, not recruiting, Boehringer Ingelheim | Recruiting --> Active, not recruiting

Severe CRS and liver injury rapidly developed in the patient after the first tarlatamab dose, which led to treatment discontinuation. This report also presents the temporal changes in serum interleukin-6 levels, highlighting its potential utility as a biomarker for the onset and severity of CRS.

P2, N=174, Recruiting, Boehringer Ingelheim | Trial primary completion date: Oct 2026 --> Jan 2027

The clinical course was aggressive, and the patient died of the disease on the 13th day of hospitalization. This case highlights the potential for aggressive T-cell lymphoma to emerge during bispecific antibody therapy, a phenomenon that has also been noted in the context of CAR-T cell therapy.

Target-mediated clearance was ~5 L/day at baseline, with an asymptote of ~0.03 L/day at steady state. With the largest covariate effect on odronextamab exposure, baseline body weight was directly correlated with CL and volume of distribution, albumin was inversely correlated with CL and volume of distribution, and baseline interleukin-10 was inversely correlated with CL.

P3, N=1000, Recruiting, European Myeloma Network B.V. | Not yet recruiting --> Recruiting